WE-D-210-02: Design and Development of Ultrasound Contrast Agents for Molecular Imaging

Abstract

The utilization of ultrasound contrast agents offers significant promise in enhancing the diagnostic capabilities of ultrasound imaging as well as offering new, noninvasive approaches for therapeutic intervention. The presentations in this session will provide an overview of current and future clinical diagnostic applications of ultrasound contrast for patient management, recent advances in the design and development of ultrasound contrast agents for molecular imaging, as well as the development of novel microbubble agents for theragnostic applications. Learning Objectives: 1. Develop an understanding of the current and future applications of ultrasound contrast agents for clinical application and preclinical research. 2. Develop a general understanding of the underlying technologies associated with improving the diagnostic capabilities of contrast– enhanced ultrasound imaging as well as potential noninvasive approaches for therapeutic intervention. Dr. Rychak is an employee of Targeson, Inc; NIH RO1 NS047603 and NIH RO1 HL074002, Holland: NIH RO1 NS047603 and NIH RO1 HL074002